Literature DB >> 31199980

Impact of phase separation morphology on release mechanism of amorphous solid dispersions.

Yi Rang Han1, Yingshan Ma1, Ping I Lee2.   

Abstract

Amorphous solid dispersions (ASDs) can phase separate in the gel phase during dissolution, lowering the chemical potential and thus the driving force for drug release. The purpose of this study is to explore the connection between amorphous phase separation in the hydrated ASD and its resulting release rate. Poorly soluble model compounds - indomethacin (IND) and ritonavir (RTV) - were formulated as ASDs using PVP as carrier. Rotating disk dissolution studies with varying drug loading levels of IND-PVP and RTV-PVP showed that the drug release was fastest at an intermediate drug loading level. This was in part due to faster erosion of the ASD at lower drug loading levels. More interestingly, at low drug loading levels, PVP and the drug co-eroded, while at high drug loading levels, PVP was released preferentially. In the case of RTV-PVP, the loading level corresponding to this transition was correlated with the change in phase separation morphology as probed by confocal fluorescence imaging studies. At low drug loading levels, the hydrophobic domains were discrete domains while at high drug loading levels, hydrophobic domains were continuous. Our results suggest that at low drug loadings, release is mediated by erosion of the polymer along with embedded drug rich droplets, whereas at high drug loadings, formation of a drug-rich domain continuous morphology leads to preferential release of the polymer-rich domains. The transition from hydrophobic discrete to hydrophobic continuous morphology occurs at the percolation threshold. We discuss the two mechanisms of phase separation and its impact on the drug release from ASDs in the context of the ternary phase diagram.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amorphous solid dispersion; Dissolution; Mechanism of release; Phase separation; Poorly soluble drug; Ternary phase diagram

Mesh:

Substances:

Year:  2019        PMID: 31199980     DOI: 10.1016/j.ejps.2019.104955

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  6 in total

1.  Impact of Surfactants on the Performance of Clopidogrel-Copovidone Amorphous Solid Dispersions: Increased Drug Loading and Stabilization of Nanodroplets.

Authors:  Clara E Correa Soto; Yi Gao; Anura S Indulkar; Keisuke Ueda; Geoff G Z Zhang; Lynne S Taylor
Journal:  Pharm Res       Date:  2022-01-10       Impact factor: 4.200

Review 2.  Continuous Manufacturing and Molecular Modeling of Pharmaceutical Amorphous Solid Dispersions.

Authors:  Amritha G Nambiar; Maan Singh; Abhishek R Mali; Dolores R Serrano; Rajnish Kumar; Anne Marie Healy; Ashish Kumar Agrawal; Dinesh Kumar
Journal:  AAPS PharmSciTech       Date:  2022-09-02       Impact factor: 4.026

3.  Influence of Particle Size and Drug Load on Amorphous Solid Dispersions Containing pH-Dependent Soluble Polymers and the Weak Base Ketoconazole.

Authors:  Marius Monschke; Kevin Kayser; Karl G Wagner
Journal:  AAPS PharmSciTech       Date:  2021-01-12       Impact factor: 3.246

4.  Hot Melt Extrusion-Triggered Amorphization as a Continuous Process for Inducing Extended Supersaturable Drug Immediate-Release from saSMSDs Systems.

Authors:  Huan Yu; Yanfei Zhang; Yinghui Ma; Huifeng Zhang; Chengyi Hao; Yong Zhang; Zhengqiang Li; Xianrong Qi; Nianqiu Shi
Journal:  Pharmaceutics       Date:  2022-03-31       Impact factor: 6.525

5.  Exploring the Role of Surfactants in Enhancing Drug Release from Amorphous Solid Dispersions at Higher Drug Loadings.

Authors:  Sugandha Saboo; Pradnya Bapat; Dana E Moseson; Umesh S Kestur; Lynne S Taylor
Journal:  Pharmaceutics       Date:  2021-05-17       Impact factor: 6.321

6.  Impact of HPMCAS on the Dissolution Performance of Polyvinyl Alcohol Celecoxib Amorphous Solid Dispersions.

Authors:  Marius Monschke; Karl G Wagner
Journal:  Pharmaceutics       Date:  2020-06-11       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.